Selected research
Industry Research
Anti-Parkinson's Disease Drugs Industry Research Report 2026
Market perspective
The global Anti-Parkinson's Disease Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Anti-Parkinson's Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Anti-Parkinson's Disease Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Anti-Parkinson's Disease Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Anti-Parkinson's Disease Drugs include Zhejiang Huahai Pharmaceutical Co., Ltd., Tianjin Lisheng Pharmaceutical Co., Ltd., Ningbo Dahongying Pharmaceutical Co., Ltd., Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Hunan Zhongnan Pharmaceutical Co., Ltd., Hangzhou Guoguang Pharmaceutical Co., Ltd., Guangzhou Kanghe Pharmaceutical Co., Ltd., Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. and Changzhou Kangpu Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Anti-Parkinson's Disease Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-Parkinson's Disease Drugs Market by Company
Zhejiang Huahai Pharmaceutical Co., Ltd.
Tianjin Lisheng Pharmaceutical Co., Ltd.
Ningbo Dahongying Pharmaceutical Co., Ltd.
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Hunan Zhongnan Pharmaceutical Co., Ltd.
Hangzhou Guoguang Pharmaceutical Co., Ltd.
Guangzhou Kanghe Pharmaceutical Co., Ltd.
Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
Changzhou Kangpu Pharmaceutical Co., Ltd.
Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
Beijing Fuyuan Pharmaceutical Co., Ltd.
Valeant
Teva Pharmaceutical
Stada Arzneimittel
Roche Holding AG
Orion
Novartis
Merck
Lundbeck
Kyowa Kirin
GSK
Endo International plc
Desitin Arzneimittel
Boehringer Ingelheim
Bausch Health
Astellas Pharma
Apokyn
Akorn
Abbvie
Anti-Parkinson's Disease Drugs Segment by Type
Anticholinergics
Dopaminergics
Anti-Parkinson's Disease Drugs Segment by Application
Pharmacy
Hospital
Clinic
Other
Anti-Parkinson's Disease Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Parkinson's Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Parkinson's Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Parkinson's Disease Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anti-Parkinson's Disease Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anti-Parkinson's Disease Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anti-Parkinson's Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Anti-Parkinson's Disease Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Anti-Parkinson's Disease Drugs Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Anti-Parkinson's Disease Drugs Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Anti-Parkinson's Disease Drugs Revenue of Manufacturers (2021-2026)
Table 9. Global Anti-Parkinson's Disease Drugs Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Anti-Parkinson's Disease Drugs Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Anti-Parkinson's Disease Drugs Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Anti-Parkinson's Disease Drugs, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Anti-Parkinson's Disease Drugs, Product Type & Application
Table 14. Global Anti-Parkinson's Disease Drugs Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Anti-Parkinson's Disease Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
Table 19. Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
Table 20. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
Table 22. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
Table 23. Tianjin Lisheng Pharmaceutical Co., Ltd. Company Information
Table 24. Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview
Table 25. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
Table 27. Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Developments
Table 28. Ningbo Dahongying Pharmaceutical Co., Ltd. Company Information
Table 29. Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview
Table 30. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
Table 32. Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Developments
Table 33. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information
Table 34. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview
Table 35. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
Table 37. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
Table 38. Hunan Zhongnan Pharmaceutical Co., Ltd. Company Information
Table 39. Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview
Table 40. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
Table 42. Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Developments
Table 43. Hangzhou Guoguang Pharmaceutical Co., Ltd. Company Information
Table 44. Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview
Table 45. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
Table 47. Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Developments
Table 48. Guangzhou Kanghe Pharmaceutical Co., Ltd. Company Information
Table 49. Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview
Table 50. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
Table 52. Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Developments
Table 53. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Company Information
Table 54. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview
Table 55. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
Table 57. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Developments
Table 58. Changzhou Kangpu Pharmaceutical Co., Ltd. Company Information
Table 59. Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview
Table 60. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
Table 62. Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Developments
Table 63. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Company Information
Table 64. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview
Table 65. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
Table 67. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Developments
Table 68. Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information
Table 69. Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview
Table 70. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
Table 72. Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Developments
Table 73. Valeant Company Information
Table 74. Valeant Business Overview
Table 75. Valeant Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Valeant Anti-Parkinson's Disease Drugs Product Portfolio
Table 77. Valeant Recent Developments
Table 78. Teva Pharmaceutical Company Information
Table 79. Teva Pharmaceutical Business Overview
Table 80. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolio
Table 82. Teva Pharmaceutical Recent Developments
Table 83. Stada Arzneimittel Company Information
Table 84. Stada Arzneimittel Business Overview
Table 85. Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
Table 87. Stada Arzneimittel Recent Developments
Table 88. Roche Holding AG Company Information
Table 89. Roche Holding AG Business Overview
Table 90. Roche Holding AG Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolio
Table 92. Roche Holding AG Recent Developments
Table 93. Orion Company Information
Table 94. Orion Business Overview
Table 95. Orion Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Orion Anti-Parkinson's Disease Drugs Product Portfolio
Table 97. Orion Recent Developments
Table 98. Novartis Company Information
Table 99. Novartis Business Overview
Table 100. Novartis Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Novartis Anti-Parkinson's Disease Drugs Product Portfolio
Table 102. Novartis Recent Developments
Table 103. Merck Company Information
Table 104. Merck Business Overview
Table 105. Merck Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Merck Anti-Parkinson's Disease Drugs Product Portfolio
Table 107. Merck Recent Developments
Table 108. Lundbeck Company Information
Table 109. Lundbeck Business Overview
Table 110. Lundbeck Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Lundbeck Anti-Parkinson's Disease Drugs Product Portfolio
Table 112. Lundbeck Recent Developments
Table 113. Kyowa Kirin Company Information
Table 114. Kyowa Kirin Business Overview
Table 115. Kyowa Kirin Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolio
Table 117. Kyowa Kirin Recent Developments
Table 118. GSK Company Information
Table 119. GSK Business Overview
Table 120. GSK Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. GSK Anti-Parkinson's Disease Drugs Product Portfolio
Table 122. GSK Recent Developments
Table 123. Endo International plc Company Information
Table 124. Endo International plc Business Overview
Table 125. Endo International plc Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Endo International plc Anti-Parkinson's Disease Drugs Product Portfolio
Table 127. Endo International plc Recent Developments
Table 128. Desitin Arzneimittel Company Information
Table 129. Desitin Arzneimittel Business Overview
Table 130. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
Table 132. Desitin Arzneimittel Recent Developments
Table 133. Boehringer Ingelheim Company Information
Table 134. Boehringer Ingelheim Business Overview
Table 135. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolio
Table 137. Boehringer Ingelheim Recent Developments
Table 138. Bausch Health Company Information
Table 139. Bausch Health Business Overview
Table 140. Bausch Health Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Bausch Health Anti-Parkinson's Disease Drugs Product Portfolio
Table 142. Bausch Health Recent Developments
Table 143. Astellas Pharma Company Information
Table 144. Astellas Pharma Business Overview
Table 145. Astellas Pharma Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolio
Table 147. Astellas Pharma Recent Developments
Table 148. Apokyn Company Information
Table 149. Apokyn Business Overview
Table 150. Apokyn Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Apokyn Anti-Parkinson's Disease Drugs Product Portfolio
Table 152. Apokyn Recent Developments
Table 153. Akorn Company Information
Table 154. Akorn Business Overview
Table 155. Akorn Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Akorn Anti-Parkinson's Disease Drugs Product Portfolio
Table 157. Akorn Recent Developments
Table 158. Abbvie Company Information
Table 159. Abbvie Business Overview
Table 160. Abbvie Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. Abbvie Anti-Parkinson's Disease Drugs Product Portfolio
Table 162. Abbvie Recent Developments
Table 163. Global Anti-Parkinson's Disease Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 164. Global Anti-Parkinson's Disease Drugs Sales by Region (2021-2026) & (K Units)
Table 165. Global Anti-Parkinson's Disease Drugs Sales Market Share by Region (2021-2026)
Table 166. Global Anti-Parkinson's Disease Drugs Sales by Region (2027-2032) & (K Units)
Table 167. Global Anti-Parkinson's Disease Drugs Sales Market Share by Region (2027-2032)
Table 168. Global Anti-Parkinson's Disease Drugs Revenue by Region (2021-2026) & (US$ Million)
Table 169. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2021-2026)
Table 170. Global Anti-Parkinson's Disease Drugs Revenue by Region (2027-2032) & (US$ Million)
Table 171. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2027-2032)
Table 172. North America Anti-Parkinson's Disease Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 173. North America Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 174. North America Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units)
Table 175. North America Anti-Parkinson's Disease Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 176. North America Anti-Parkinson's Disease Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 177. Europe Anti-Parkinson's Disease Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 178. Europe Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 179. Europe Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units)
Table 180. Europe Anti-Parkinson's Disease Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 181. Europe Anti-Parkinson's Disease Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 182. Asia Pacific Anti-Parkinson's Disease Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 183. Asia Pacific Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 184. Asia Pacific Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units)
Table 185. Asia Pacific Anti-Parkinson's Disease Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 186. Asia Pacific Anti-Parkinson's Disease Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 187. South America Anti-Parkinson's Disease Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 188. South America Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 189. South America Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units)
Table 190. South America Anti-Parkinson's Disease Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 191. South America Anti-Parkinson's Disease Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 192. Middle East and Africa Anti-Parkinson's Disease Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 193. Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units)
Table 194. Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units)
Table 195. Middle East and Africa Anti-Parkinson's Disease Drugs Revenue by Country (2021-2026) & (US$ Million)
Table 196. Middle East and Africa Anti-Parkinson's Disease Drugs Revenue by Country (2027-2032) & (US$ Million)
Table 197. Global Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units)
Table 198. Global Anti-Parkinson's Disease Drugs Sales by Type (2027-2032) & (K Units)
Table 199. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2026)
Table 200. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2027-2032)
Table 201. Global Anti-Parkinson's Disease Drugs Revenue by Type (2021-2026) & (US$ Million)
Table 202. Global Anti-Parkinson's Disease Drugs Revenue by Type (2027-2032) & (US$ Million)
Table 203. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2021-2026)
Table 204. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2027-2032)
Table 205. Global Anti-Parkinson's Disease Drugs Price by Type (2021-2026) & (US$/Unit)
Table 206. Global Anti-Parkinson's Disease Drugs Price by Type (2027-2032) & (US$/Unit)
Table 207. Global Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units)
Table 208. Global Anti-Parkinson's Disease Drugs Sales by Application (2027-2032) & (K Units)
Table 209. Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2026)
Table 210. Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2027-2032)
Table 211. Global Anti-Parkinson's Disease Drugs Revenue by Application (2021-2026) & (US$ Million)
Table 212. Global Anti-Parkinson's Disease Drugs Revenue by Application (2027-2032) & (US$ Million)
Table 213. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2021-2026)
Table 214. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2027-2032)
Table 215. Global Anti-Parkinson's Disease Drugs Price by Application (2021-2026) & (US$/Unit)
Table 216. Global Anti-Parkinson's Disease Drugs Price by Application (2027-2032) & (US$/Unit)
Table 217. Key Raw Materials
Table 218. Raw Materials Key Suppliers
Table 219. Anti-Parkinson's Disease Drugs Distributors List
Table 220. Anti-Parkinson's Disease Drugs Customers List
Table 221. Anti-Parkinson's Disease Drugs Industry Trends
Table 222. Anti-Parkinson's Disease Drugs Industry Drivers
Table 223. Anti-Parkinson's Disease Drugs Industry Restraints
Table 224. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Anti-Parkinson's Disease Drugs Product Image
Figure 5. Global Anti-Parkinson's Disease Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Anti-Parkinson's Disease Drugs Market Size (2021-2032) & (US$ Million)
Figure 7. Global Anti-Parkinson's Disease Drugs Sales (2021-2032) & (K Units)
Figure 8. Global Anti-Parkinson's Disease Drugs Average Price (US$/Unit) & (2021-2032)
Figure 9. Anticholinergics Product Image
Figure 10. Dopaminergics Product Image
Figure 11. Pharmacy Product Image
Figure 12. Hospital Product Image
Figure 13. Clinic Product Image
Figure 14. Other Product Image
Figure 15. Global Anti-Parkinson's Disease Drugs Revenue Share by Manufacturers in 2025
Figure 16. Global Manufacturers of Anti-Parkinson's Disease Drugs, Manufacturing Sites & Headquarters
Figure 17. Global Top 5 and 10 Anti-Parkinson's Disease Drugs Players Market Share by Revenue in 2025
Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 19. Global Anti-Parkinson's Disease Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 20. Global Anti-Parkinson's Disease Drugs Sales by Region in 2025
Figure 21. Global Anti-Parkinson's Disease Drugs Revenue by Region in 2025
Figure 22. North America Anti-Parkinson's Disease Drugs Market Size by Country in 2025
Figure 23. North America Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2032)
Figure 24. North America Anti-Parkinson's Disease Drugs Revenue Market Share by Country (2021-2032)
Figure 25. United States Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 26. Canada Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 27. Mexico Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 28. Europe Anti-Parkinson's Disease Drugs Market Size by Country in 2025
Figure 29. Europe Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2032)
Figure 30. Europe Anti-Parkinson's Disease Drugs Revenue Market Share by Country (2021-2032)
Figure 31. Germany Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 32. France Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. U.K. Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. Italy Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. Russia Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Spain Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Netherlands Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Switzerland Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Sweden Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. Poland Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Asia Pacific Anti-Parkinson's Disease Drugs Market Size by Country in 2025
Figure 42. Asia Pacific Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2032)
Figure 43. Asia Pacific Anti-Parkinson's Disease Drugs Revenue Market Share by Country (2021-2032)
Figure 44. China Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. Japan Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. South Korea Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. India Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. Australia Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. Taiwan Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. Southeast Asia Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Southeast Asia Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. South America Anti-Parkinson's Disease Drugs Market Size by Country in 2025
Figure 53. South America Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2032)
Figure 54. South America Anti-Parkinson's Disease Drugs Revenue Market Share by Country (2021-2032)
Figure 55. Brazil Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 56. Argentina Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 57. Chile Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 58. Middle East and Africa Anti-Parkinson's Disease Drugs Market Size by Country in 2025
Figure 59. Middle East and Africa Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2032)
Figure 60. Middle East and Africa Anti-Parkinson's Disease Drugs Revenue Market Share by Country (2021-2032)
Figure 61. Egypt Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 62. South Africa Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 63. Israel Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 64. Türkiye Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 65. GCC Countries Anti-Parkinson's Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 66. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2032)
Figure 67. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2021-2032)
Figure 68. Global Anti-Parkinson's Disease Drugs Price (US$/Unit) by Type (2021-2032)
Figure 69. Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2032)
Figure 70. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2021-2032)
Figure 71. Global Anti-Parkinson's Disease Drugs Price (US$/Unit) by Application (2021-2032)
Figure 72. Anti-Parkinson's Disease Drugs Value Chain
Figure 73. Anti-Parkinson's Disease Drugs Production Mode & Process
Figure 74. Direct Comparison with Distribution Share
Figure 75. Distributors Profiles
Figure 76. Anti-Parkinson's Disease Drugs Industry Opportunities and Challenges
Scope & coverage.
Types
- Anticholinergics
- Dopaminergics
Applications
- Pharmacy
- Hospital
- Clinic
- Other
Companies covered
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Tianjin Lisheng Pharmaceutical Co., Ltd.
- Ningbo Dahongying Pharmaceutical Co., Ltd.
- Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
- Hunan Zhongnan Pharmaceutical Co., Ltd.
- Hangzhou Guoguang Pharmaceutical Co., Ltd.
- Guangzhou Kanghe Pharmaceutical Co., Ltd.
- Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
- Changzhou Kangpu Pharmaceutical Co., Ltd.
- Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
- Beijing Fuyuan Pharmaceutical Co., Ltd.
- Valeant
- Teva Pharmaceutical
- Stada Arzneimittel
- Roche Holding AG
- Orion
- Novartis
- Merck
- Lundbeck
- Kyowa Kirin
- GSK
- Endo International plc
- Desitin Arzneimittel
- Boehringer Ingelheim
- Bausch Health
- Astellas Pharma
- Apokyn
- Akorn
- Abbvie
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anti-Parkinson's Disease Drugs Market Size (2021-2032)
- 2.2.2 Global Anti-Parkinson's Disease Drugs Sales (2021-2032)
- 2.2.3 Global Anti-Parkinson's Disease Drugs Market Average Price (2021-2032)
- 2.3 Anti-Parkinson's Disease Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Anticholinergics
- 2.3.3 Dopaminergics
- 2.4 Anti-Parkinson's Disease Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pharmacy
- 2.4.3 Hospital
- 2.4.4 Clinic
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anti-Parkinson's Disease Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anti-Parkinson's Disease Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Anti-Parkinson's Disease Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Anti-Parkinson's Disease Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Anti-Parkinson's Disease Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anti-Parkinson's Disease Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anti-Parkinson's Disease Drugs, Product Type & Application
- 3.8 Global Manufacturers of Anti-Parkinson's Disease Drugs, Established Date
- 3.9 Global Anti-Parkinson's Disease Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Zhejiang Huahai Pharmaceutical Co., Ltd.
- 4.1.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
- 4.1.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
- 4.1.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
- 4.1.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
- 4.2 Tianjin Lisheng Pharmaceutical Co., Ltd.
- 4.2.1 Tianjin Lisheng Pharmaceutical Co., Ltd. Company Information
- 4.2.2 Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview
- 4.2.3 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
- 4.2.5 Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Developments
- 4.3 Ningbo Dahongying Pharmaceutical Co., Ltd.
- 4.3.1 Ningbo Dahongying Pharmaceutical Co., Ltd. Company Information
- 4.3.2 Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview
- 4.3.3 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
- 4.3.5 Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Developments
- 4.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
- 4.4.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information
- 4.4.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview
- 4.4.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
- 4.4.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
- 4.5 Hunan Zhongnan Pharmaceutical Co., Ltd.
- 4.5.1 Hunan Zhongnan Pharmaceutical Co., Ltd. Company Information
- 4.5.2 Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview
- 4.5.3 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
- 4.5.5 Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Developments
- 4.6 Hangzhou Guoguang Pharmaceutical Co., Ltd.
- 4.6.1 Hangzhou Guoguang Pharmaceutical Co., Ltd. Company Information
- 4.6.2 Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview
- 4.6.3 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
- 4.6.5 Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Developments
- 4.7 Guangzhou Kanghe Pharmaceutical Co., Ltd.
- 4.7.1 Guangzhou Kanghe Pharmaceutical Co., Ltd. Company Information
- 4.7.2 Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview
- 4.7.3 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
- 4.7.5 Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Developments
- 4.8 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
- 4.8.1 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Company Information
- 4.8.2 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview
- 4.8.3 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
- 4.8.5 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Developments
- 4.9 Changzhou Kangpu Pharmaceutical Co., Ltd.
- 4.9.1 Changzhou Kangpu Pharmaceutical Co., Ltd. Company Information
- 4.9.2 Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview
- 4.9.3 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
- 4.9.5 Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Developments
- 4.10 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
- 4.10.1 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Company Information
- 4.10.2 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview
- 4.10.3 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
- 4.10.5 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Developments
- 4.11 Beijing Fuyuan Pharmaceutical Co., Ltd.
- 4.11.1 Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information
- 4.11.2 Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview
- 4.11.3 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
- 4.11.5 Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Developments
- 4.12 Valeant
- 4.12.1 Valeant Company Information
- 4.12.2 Valeant Business Overview
- 4.12.3 Valeant Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Valeant Anti-Parkinson's Disease Drugs Product Portfolio
- 4.12.5 Valeant Recent Developments
- 4.13 Teva Pharmaceutical
- 4.13.1 Teva Pharmaceutical Company Information
- 4.13.2 Teva Pharmaceutical Business Overview
- 4.13.3 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolio
- 4.13.5 Teva Pharmaceutical Recent Developments
- 4.14 Stada Arzneimittel
- 4.14.1 Stada Arzneimittel Company Information
- 4.14.2 Stada Arzneimittel Business Overview
- 4.14.3 Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
- 4.14.5 Stada Arzneimittel Recent Developments
- 4.15 Roche Holding AG
- 4.15.1 Roche Holding AG Company Information
- 4.15.2 Roche Holding AG Business Overview
- 4.15.3 Roche Holding AG Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolio
- 4.15.5 Roche Holding AG Recent Developments
- 4.16 Orion
- 4.16.1 Orion Company Information
- 4.16.2 Orion Business Overview
- 4.16.3 Orion Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Orion Anti-Parkinson's Disease Drugs Product Portfolio
- 4.16.5 Orion Recent Developments
- 4.17 Novartis
- 4.17.1 Novartis Company Information
- 4.17.2 Novartis Business Overview
- 4.17.3 Novartis Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Novartis Anti-Parkinson's Disease Drugs Product Portfolio
- 4.17.5 Novartis Recent Developments
- 4.18 Merck
- 4.18.1 Merck Company Information
- 4.18.2 Merck Business Overview
- 4.18.3 Merck Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Merck Anti-Parkinson's Disease Drugs Product Portfolio
- 4.18.5 Merck Recent Developments
- 4.19 Lundbeck
- 4.19.1 Lundbeck Company Information
- 4.19.2 Lundbeck Business Overview
- 4.19.3 Lundbeck Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Lundbeck Anti-Parkinson's Disease Drugs Product Portfolio
- 4.19.5 Lundbeck Recent Developments
- 4.20 Kyowa Kirin
- 4.20.1 Kyowa Kirin Company Information
- 4.20.2 Kyowa Kirin Business Overview
- 4.20.3 Kyowa Kirin Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolio
- 4.20.5 Kyowa Kirin Recent Developments
- 4.21 GSK
- 4.21.1 GSK Company Information
- 4.21.2 GSK Business Overview
- 4.21.3 GSK Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.21.4 GSK Anti-Parkinson's Disease Drugs Product Portfolio
- 4.21.5 GSK Recent Developments
- 4.22 Endo International plc
- 4.22.1 Endo International plc Company Information
- 4.22.2 Endo International plc Business Overview
- 4.22.3 Endo International plc Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.22.4 Endo International plc Anti-Parkinson's Disease Drugs Product Portfolio
- 4.22.5 Endo International plc Recent Developments
- 4.23 Desitin Arzneimittel
- 4.23.1 Desitin Arzneimittel Company Information
- 4.23.2 Desitin Arzneimittel Business Overview
- 4.23.3 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.23.4 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
- 4.23.5 Desitin Arzneimittel Recent Developments
- 4.24 Boehringer Ingelheim
- 4.24.1 Boehringer Ingelheim Company Information
- 4.24.2 Boehringer Ingelheim Business Overview
- 4.24.3 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.24.4 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolio
- 4.24.5 Boehringer Ingelheim Recent Developments
- 4.25 Bausch Health
- 4.25.1 Bausch Health Company Information
- 4.25.2 Bausch Health Business Overview
- 4.25.3 Bausch Health Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.25.4 Bausch Health Anti-Parkinson's Disease Drugs Product Portfolio
- 4.25.5 Bausch Health Recent Developments
- 4.26 Astellas Pharma
- 4.26.1 Astellas Pharma Company Information
- 4.26.2 Astellas Pharma Business Overview
- 4.26.3 Astellas Pharma Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.26.4 Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolio
- 4.26.5 Astellas Pharma Recent Developments
- 4.27 Apokyn
- 4.27.1 Apokyn Company Information
- 4.27.2 Apokyn Business Overview
- 4.27.3 Apokyn Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.27.4 Apokyn Anti-Parkinson's Disease Drugs Product Portfolio
- 4.27.5 Apokyn Recent Developments
- 4.28 Akorn
- 4.28.1 Akorn Company Information
- 4.28.2 Akorn Business Overview
- 4.28.3 Akorn Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.28.4 Akorn Anti-Parkinson's Disease Drugs Product Portfolio
- 4.28.5 Akorn Recent Developments
- 4.29 Abbvie
- 4.29.1 Abbvie Company Information
- 4.29.2 Abbvie Business Overview
- 4.29.3 Abbvie Anti-Parkinson's Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.29.4 Abbvie Anti-Parkinson's Disease Drugs Product Portfolio
- 4.29.5 Abbvie Recent Developments
5 Global Anti-Parkinson's Disease Drugs Market Scenario by Region
- 5.1 Global Anti-Parkinson's Disease Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anti-Parkinson's Disease Drugs Sales by Region: 2021-2032
- 5.2.1 Global Anti-Parkinson's Disease Drugs Sales by Region: 2021-2026
- 5.2.2 Global Anti-Parkinson's Disease Drugs Sales by Region: 2027-2032
- 5.3 Global Anti-Parkinson's Disease Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Anti-Parkinson's Disease Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Anti-Parkinson's Disease Drugs Revenue by Region: 2027-2032
- 5.4 North America Anti-Parkinson's Disease Drugs Market Facts & Figures by Country
- 5.4.1 North America Anti-Parkinson's Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anti-Parkinson's Disease Drugs Sales by Country (2021-2032)
- 5.4.3 North America Anti-Parkinson's Disease Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Anti-Parkinson's Disease Drugs Market Facts & Figures by Country
- 5.5.1 Europe Anti-Parkinson's Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anti-Parkinson's Disease Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Anti-Parkinson's Disease Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Anti-Parkinson's Disease Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anti-Parkinson's Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anti-Parkinson's Disease Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anti-Parkinson's Disease Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anti-Parkinson's Disease Drugs Market Facts & Figures by Country
- 5.7.1 South America Anti-Parkinson's Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anti-Parkinson's Disease Drugs Sales by Country (2021-2032)
- 5.7.3 South America Anti-Parkinson's Disease Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Anti-Parkinson's Disease Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anti-Parkinson's Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anti-Parkinson's Disease Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Anti-Parkinson's Disease Drugs Sales by Type (2021-2032)
- 6.1.1 Global Anti-Parkinson's Disease Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Anti-Parkinson's Disease Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Anti-Parkinson's Disease Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Anti-Parkinson's Disease Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anti-Parkinson's Disease Drugs Sales by Application (2021-2032)
- 7.1.1 Global Anti-Parkinson's Disease Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Anti-Parkinson's Disease Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Anti-Parkinson's Disease Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Anti-Parkinson's Disease Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anti-Parkinson's Disease Drugs Value Chain Analysis
- 8.1.1 Anti-Parkinson's Disease Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anti-Parkinson's Disease Drugs Production Mode & Process
- 8.2 Anti-Parkinson's Disease Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anti-Parkinson's Disease Drugs Distributors
- 8.2.3 Anti-Parkinson's Disease Drugs Customers
9 Global Anti-Parkinson's Disease Drugs Analyzing Market Dynamics
- 9.1 Anti-Parkinson's Disease Drugs Industry Trends
- 9.2 Anti-Parkinson's Disease Drugs Industry Drivers
- 9.3 Anti-Parkinson's Disease Drugs Industry Opportunities and Challenges
- 9.4 Anti-Parkinson's Disease Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst